Last $40.76 USD
Change Today +0.86 / 2.16%
Volume 2.0M
ISIS On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

isis pharmaceuticals inc (ISIS) Snapshot

Open
$40.47
Previous Close
$39.90
Day High
$41.45
Day Low
$40.05
52 Week High
02/24/14 - $62.66
52 Week Low
05/9/14 - $22.25
Market Cap
4.8B
Average Volume 10 Days
2.1M
EPS TTM
$-0.80
Shares Outstanding
117.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ISIS PHARMACEUTICALS INC (ISIS)

isis pharmaceuticals inc (ISIS) Related Businessweek News

No Related Businessweek News Found

isis pharmaceuticals inc (ISIS) Details

Isis Pharmaceuticals, Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 31 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, including neurological disorders; and cancer. The company has strategic alliances and collaboration agreements primarily with AstraZeneca AB, Biogen Idec MA Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genzyme Corporation, GlaxoSmithKline, Hoffman-La Roche Inc., F. Hoffmann-La Roche Ltd., Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Excaliard Pharmaceuticals, Inc., iCo Therapeutics Inc., OncoGenex Technologies Inc., and Xenon Pharmaceuticals Inc. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

isis pharmaceuticals inc (ISIS) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $1.5M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $581.4K
Chief Operating Officer, Corporate Secretary,...
Total Annual Compensation: $1.2M
Senior Vice President of Antisense Research
Total Annual Compensation: $631.6K
Senior Vice President of Development
Total Annual Compensation: $624.4K
Compensation as of Fiscal Year 2013.

isis pharmaceuticals inc (ISIS) Key Developments

Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 3 study evaluating ISIS-APOCIII(Rx) in patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide. The Phase 3 study of ISIS-APOCIII(Rx) is a randomized, double-blind, placebo-controlled, six month study in approximately 50 patients diagnosed with FCS. The study will evaluate the efficacy and safety of a 300 mg once weekly dose of ISIS-APOCIII(Rx). The primary endpoint of the study is percent change in fasting triglycerides from baseline after three months of dosing. In a Phase 2 study, FCS patients treated with ISIS-APOCIII(Rx) experienced decreases in triglycerides of up to more than 1,500 mg/dL. Isis has also evaluated ISIS-APOCIII(Rx) in a broad Phase 2 program. In these studies in patients with very high to extremely high triglyceride levels, patients treated with ISIS-APOCIII(Rx) achieved substantial lowering of triglycerides (mean percent reductions of up to 71%) and apoC-III (mean percent reductions of up to 88%) and increasing of HDL-cholesterol (mean percent increases of up to 78%). ISIS-APOCIII(Rx) is designed to target apoC-III, a protein produced in the liver that plays a central role in the regulation of serum triglycerides. ApoC-III is a genetically validated target for lowering triglycerides. Independent studies have demonstrated a link between lower apoC-III activity, which results in lower triglyceride levels, and reduced cardiovascular disease. In addition to developing ISIS-APOCIII(Rx) for patients with FCS, Isis is also developing ISIS-APOCIII(Rx) for patients with severely elevated triglycerides, greater than 880 mg/dL, a condition that affects an estimated 50,000 patients in the United States and Europe. These patients not only have a high risk of pancreatitis but also have a high risk of type 2 diabetes and cardiovascular disease. Currently available therapies do not reduce triglycerides sufficiently in many of these patients to reduce these health risks. Isis plans to initiate the Phase 3 program in patients with severely elevated triglycerides in 2014.

First Infant Receives Their First Dose of ISIS-SMN in the Isis Pharmaceuticals, Inc

On August 21, 2014, the first infant received their first dose of ISIS-SMN in the Isis Pharmaceuticals, Inc. Phase 3 study, ENDEAR, which is evaluating ISIS-SMN in infants with spinal muscular atrophy (SMA). Isis earned an $18 million milestone payment from its development partner, Biogen Idec International Holding Ltd. as a result of Isis' achievement of this milestone event. The ENDEAR study, is the first Phase 3 clinical study for ISIS-SMN. Isis plans to initiate a second pivotal study in children with SMA later in 2014 and additional studies are in the planning stages.

ISIS Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Revenue Guidance for the Full Year 2014

ISIS Pharmaceuticals Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the second quarter, the company reported total revenue was $57,076,000 compared with $38,092,000 for the same period in the last year. Loss from operations was $6,650,000 compared with $7,928,000 for the same period in the last year. Loss before income tax was $11,200,000 compared with $11,307,000 for the same period in the last year. Net loss was $12,081,000 compared with $10,126,000 for the same period in the last year. Diluted net loss per share was $0.10 compared with $0.09 for the same period in the last year. Pro forma operating profit was $1.1 million. For the six months, the company reported total revenue was $85,237,000 compared with $81,451,000 for the same period in the last year. Loss from operations was $121,554,000 compared with $87,755,000 for the same period in the last year. Loss before income tax was $44,756,000 compared with $13,042,000 for the same period in the last year. Net loss was $43,361,000 compared with $11,798,000 for the same period in the last year. Diluted net loss per share was $0.37 compared with $0.11 for the same period in the last year. The company provided revenue guidance for the full year 2014. For the period, the company's revenue, most significantly milestone payments, the company have earned more than $85 million so far this year and the company is on track to meet guidance of more than $150 million in total revenue for this year 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $40.76 USD +0.86

ISIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ISIS.
View Industry Companies
 

Industry Analysis

ISIS

Industry Average

Valuation ISIS Industry Range
No financial data is available for ISIS.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit www.isispharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.